このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke Patients (Crypto PulseON)

To evaluate the usability of the Pulse ON wearable device in patients with cryptogenic stroke/TIA

調査の概要

状態

募集

条件

介入・治療

詳細な説明

The research project aims to evaluate the usability of a new device for detecting heart rhythm disturbances, especially atrial fibrillation (AF) in people who have had a stroke or mini-stroke (transient ischaemic attack [TIA]) of unknown cause (cryptogenic stroke). AF can be a major cause of disabling strokes and AF-related stroke risk is significantly reduced by starting specific blood thinners called anticoagulants.

Stroke is a major public health concern worldwide, with approximately 100,000 cases annually in the UK alone, making it a leading cause of death and disability. Around 38,000 stroke-related deaths occur each year, and many survivors experience significant long-term impairment. The vast majority (~90%) are ischaemic strokes, yet in 20-40% of cases, no definitive underlying cause is identified, despite extensive evaluation. These cryptogenic stroke cases remain a diagnostic challenge. Cryptogenic strokes are more common in younger stroke patients (<60 years) but can affect all age groups.

AF is the most common arrhythmia and a well-established cause of ischaemic stroke, responsible for 15-30% of cases. However, in cryptogenic stroke, AF often goes undiagnosed because it can come and go (i.e. is paroxysmal) and can be asymptomatic in nature, with episodes that can last for short periods of time but carry high risk of stroke. Early and accurate diagnosis of AF is crucial, as clinical trials have demonstrated the efficacy of oral anticoagulation in significantly reducing stroke risk. Thus, identifying AF in cryptogenic stroke patients can directly impact management by shifting treatment towards anticoagulation.

Background. Detecting AF in cryptogenic stroke is a major challenge and many methods fail to capture episodes of AF that come and go (paroxysmal). Conventional AF detection methods, such as in-hospital cardiac monitoring, serial ECGs, Holter monitors, external event recorders, wearable devices and implantable loop recorders (ILRs), vary in effectiveness. ILRs are small devices (the size of a pen-lid) implanted under the skin of the left chest wall and have a battery life of around three years. They have demonstrated superior diagnostic sensitivity, as highlighted in the CRYSTAL-AF trial, which showed their advantage over standard monitoring in cryptogenic stroke (AF detection rate of 12.4% for ILRs vs 2% for standard monitoring at 12 months). However, ILRs are invasive (which comes with its own procedure-related risks), costly, and may not be suitable for all patients.2 We want to evaluate a different type of AF detection device (the PulseON Arrhythmia Monitor System) that is not currently used in standard care, one that's wrist worn and non-invasive.

Proposed trial We propose a single centre, single arm feasibility pilot study designed to evaluate how practical and user friendly it is for participants to use the PulseON Arrhythmia Monitor System for detecting AF in addition to their normal standard of care. The study will explore whether participants can wear the device as intended, respond to alerts and successfully carry out ECG recordings using the system, whilst capturing their user experience and having their heart tracings closely monitored by health care professionals.

Trial population At UHCW NHS Trust, we manage approximately 1,400 strokes annually (with 350 classified as cryptogenic), many of whom will need to be monitored for AF. While most patients undergo Holter monitoring for AF, a smaller subset receive ILRs but their use is limited due their cost and invasive nature. The introduction of this PulseON device could significantly enhance AF detection, improving patient outcomes, be more cost-effective and optimise resource utilisation within our hospital and the broader NHS. We plan to evaluate whether cardiac monitoring with the PulseON system is feasible in patients with cryptogenic stroke/TIA. This evaluation project may inform wider research into this device and potential NHS implementation.

Treatment / Intervention We aim to recruit twelve patients who have experienced a cryptogenic ischaemic stroke or TIA within the past six months for this project. All patients who participate in the project will receive conventional standard of care investigations (Holter monitoring or ILR) in addition to the PulseON Arrhythmia monitoring system. The data collected will include experience of device usability via an MS forms questionnaire and a follow-up patient interview, baseline demographics, usability data and any newly detected arrhythmia observed from the heart tracing data, in particular AF (defined as an episode of AF lasting >30seconds). Any arrhythmia documented from the PulseON device will be uploaded and stored in an encrypted and secure cloud-based server.

Participants heart tracing data will be collected and reviewed by a suitably qualified healthcare professional within the study team (primarily the Principal Investigator).The reviewer will assess any detected cardiac events to determine their clinical significance and, when appropriate, will escalate relevant findings to the participant's clinical care team. This process ensures that any new or emerging information arising from the study is used to support and inform the provision of standard clinical care for participants.

研究の種類

観察的

入学 (推定)

12

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Coventry、イギリス、CV2 2DX
        • 募集
        • University Hospital Coventry & Warwickshire NHS Trust

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Patients diagnosed with cryptogenic stroke/TIA

説明

Inclusion Criteria:

  • Adult patients (>18yrs old) diagnosed with cryptogenic stroke / TIA
  • Baseline electrocardiogram (ECG), Holter monitor and echocardiogram as part of the standard of care cardiac work-up in the diagnosis of cryptogenic stroke

Exclusion Criteria:

  • Patients unwilling or unable to wear the PulseON arrhythmia detection device.
  • Known pre-existing AF or atrial arrhythmia diagnosis.
  • Participants without capacity will be excluded from this study.
  • Participants who are pregnant will be excluded from this study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Usability & Feasibility of PulseON wearable device
時間枠:1 month minimum

We will collect patient questionnaires and perform patient interviews to gather data on the PulseON device for usability and feasibility data.

Formal feedback from health professionals who follow up the trial participants via the PulseON arrhythmia monitoring system online will be obtained.

1 month minimum

二次結果の測定

結果測定
メジャーの説明
時間枠
The prevalence of AF in people who have had cryptogenic ischaemic stroke or TIA.
時間枠:1 month

The ability of Pulse ON in detecting AF on ECG and how it differs from the standard of care (ECG, Holter monitoring or ILR)

1 month
Baseline characteristics of cohort
時間枠:1 month

Baseline demographic and clinical characteristics

1 month

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Faizel Osman、University Hospital Coventry & Warwickshire
  • 主任研究者:Ven G Lim、University Hospital Coventry & Warwickshire

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年9月16日

一次修了 (推定)

2027年1月1日

研究の完了 (推定)

2027年3月1日

試験登録日

最初に提出

2026年11月11日

QC基準を満たした最初の提出物

2026年11月11日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • FO658425

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。